Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An open label trial of OZ101 as an add-on therapy for the treatment of type 2 diabetes mellitus in patients on sulphonylurea therapy.

Trial Profile

An open label trial of OZ101 as an add-on therapy for the treatment of type 2 diabetes mellitus in patients on sulphonylurea therapy.

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 16 Jul 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs OZ 101 (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Sponsors OzStar Therapeutics
  • Most Recent Events

    • 10 Dec 2018 Sydney site closed as of 05/12/2018, 22 patients enrolled in Bangalore India site. The site anticipates to recruit 8 additional patients prior to Christmas.
    • 10 Dec 2018 Anticipated date last participant enrolled is 12/28/2018 as reported by Australian New Zealand Clinical Trials Registry
    • 10 Dec 2018 Planned number of patients changed from 60 to 30 as Sydney site has been closed as of 05/12/2018 due to inability to find type 2 diabetes patients required for the study. Therefore, only India site will be recruiting 30 patients.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top